Clinical Trial

Acute Effects of Isoenergetic HIIE Vs. MICE on Key Parameters of Fat Mass Loss in Young Females with Overweight or Obesity

Study acronym: COMEFIT
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 11, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Overweight and obesity, particularly increased total and/or abdominal fat mass (FM), are strongly linked to the development of cardiovascular diseases. Managing obesity effectively requires lifestyle and dietary modifications, including increased physical activity. Among the various exercise strategies, Moderate-Intensity Continuous Training (MICT) and High-Intensity Interval Training (HIIT) are widely recommended for reducing FM. Compared to MICT, HIIT is a time-efficient approach, often perceived as more enjoyable, and has been shown to promote greater total and abdominal fat loss in a shorter period. However, the precise mechanisms underlying this enhanced fat loss remain unclear. This study aims to compare the acute effects of two isoenergetic exercise sessions - MICE (Moderate-Intensity Continuous Exercise) and HIIE (High-Intensity Interval Exercise) - on key physiological responses involved in fat mass loss. Specifically, we will assess plasma catecholamine levels during exercise and recovery, as well as oxygen consumption, substrate oxidation, and appetite over the 2-hour post-exercise period in young females with overweight or obesity. By elucidating the role of catecholaminergic stimulation as a potential regulator of fat mass loss, this research could provide valuable insights for optimizing exercise strategies in weight management and metabolic health.
Trial Details
NCT Number NCT06868862
Lead Sponsor Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques
Collaborators: LAPEF laboratory, Sao paulo
Conditions Overweight and Obese Adults, High Intensity Interval Exercise (HIIE)
Enrollment 15 participants
Start Date 2025-02-01
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-11